Johnson & Johnson Reports Positive CAPLYTA Phase 3 Mania Data
Titusville, New Jersey, U.S., September 21, 2026 Johnson & Johnson has announced positive topline results from a pivotal Phase...
Phase 3 Clinical Trial
Advertisement
Novo Nordisk Reports Positive Phase 3 CagriSema Resultsx
Bagsværd, Denmark, September 21, 2026 Novo Nordisk has announced topline results from two Phase 3 trials evaluating CagriSema, an...
Vera Therapeutics TRUTAKNA Shows Two-Year Kidney Benefit
Brisbane, California, USA, September 15, 2026 Vera Therapeutics has announced final efficacy results from the Phase 3 ORIGIN 3...
Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer
Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...
Advertisements
Kazia Doses First Patient in Pediatric AT/RT Study
Sydney, Australia, September 10, 2026 Kazia Therapeutics Limited has announced that the first patient has been dosed in the...
BioMarin Reports Positive Phase 3 VOXZOGO Data
San Rafael, California, September 9, 2026 BioMarin Pharmaceutical Inc. has announced the publication of positive Phase 3 CANOPY-HCH-3 results...
Johnson & Johnson Highlights New Neuropsychiatry Data
Titusville, New Jersey, U.S., September 8, 2026 Johnson & Johnson is set to present new clinical and real-world evidence...
Belite Bio Files Japan NDA for Tinlarebant in Stargardt Disease
San Diego, California, U.S., September 8, 2026 Belite Bio has announced the submission of a New Drug Application (NDA)...
Novartis and Ionis Pharmaceuticals Face Setback in Pelacarsen Trial
Carlsbad, California — September 4, 2026 Ionis Pharmaceuticals and partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON...
Advertisement
